Associate Professor of Medicine, Mayo Medical School
Oncology
Dr. Helen J. Ross, MD
|
|
Give Review
Dr. Helen J. Ross is an expert in the field of Oncology. She went to medical school at David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a top medical college. David Geffen School of Medicine at UCLA has a rank of 13 in research and a 7 in primary care Dr. Helen J. Ross is also published. She has 35 publications published. The lastest publication: "Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers.'
Publications
- PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizu...
- Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced Malignant pleural mesothelioma.
- NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non-Small-Cell Lung Cance...
- Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung Cancer.
- Outcomes of Minimally Invasive Esophagectomy in Esophageal Cancer After Neoadjuvant Chemoradiotherapy.
- A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: North Central Cancer...
- A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-sta...
- An Early Experience Using the Technique of TransOral OrVil EEA Stapler for Minimally Invasive Transthoracic Esophagectomy.
- Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable n...
- Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell Lung ca...
- Single-agent versus combination chemotherapy in patients with advanced non-small cell lung Cancer and a performance status of 2: prognostic factors and treatment selec...
- Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected ...
- Localized gastric or gastroesophageal Cancer - chemoradiation is a pertinent component of adjuvant treatment for patients at high risk of relapse.
- Biphasic pulmonary blastoma with germ Cell differentiation in a 36-year-old man.
- Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 pati...
- Selective dose escalation of chemoradiotherapy for locally advanced esophageal Cancer.
- Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or meta...
- A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cel...
- Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with Malignant pleural mesothelioma: outcomes of an expanded access program.
- Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar Carcinoma.
- A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell Lung carcinoma.
- Pemetrexed alone or in combination with cisplatin in previously treated Malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
- Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis Lung carcinoma.
- Neuroendocrine-like differentiation of non-small cell Lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1.
- Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
- Apoptosis of non-small-cell lung Cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim.
- Selective dose escalation of chemoradiotherapy for esophageal Cancer: role of treatment intensification.
- Effects of metabolic stimulation on cardiac allograft recovery.
- Phase I/II trial of low dose cyclosporin A with EP for advanced non-small cell lung Cancer.
- Cyclosporin A enhances paclitaxel toxicity against Leukemia and respiratory epithelial cancers.
- The antiproliferative effect of trans-retinoic acid is associated with selective induction of interleukin-1 beta, a cytokine that directly inhibits growth of Lung canc...
- Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment.
- Cytokine messenger RNA stability is enhanced in tumor Cells.
- Tumor necrosis factor induces hemorrhagic necrosis of a sarcoma.
Schools
University of California At Los Angeles
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
UCLA Medical Center -
Cedars-Sinai Medical Center -
David Geffen School of Medicine at UCLA
Hospital
-
Mayo Clinic - Phoenix/Scottsdale, Arizona
Drug Facts
| NPI NUMBER | 1841282159 | |
| NPPES Provider LastName | ROSS | |
| NPPES Provider FirstName | HELEN | |
| NPPES Provider ZIPCode | 852595404 | |
| NPPES Provider State | AZ | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 338.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 3.85 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841282159 |
| Last Name Of The Provider | ROSS |
| First Name Of The Provider | HELEN |
| View All |
Similar Doctors
|
Dr. Irwin L. Levey, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Giraldo Kato, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick J. Donovan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thai H. Ho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip J. Federio, MD |
|
|
Dr. Alan H. Bryce, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald W. Northfelt, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Samuel Ejadi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen S. Anderson, MD |
|
|
Dr. Nandita Khera, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan Robetorye, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharon D. Gburek, MD
This Doctor is OpenDoctor Recommended.
|